first patented BACE1 protease inhib. of series

Ph. II/III in Alzheimer’s, discontinued (tox.)

from phenotypic screen and SBDD

J. Med. Chem., Feb. 15, 2021

Shionogi Pharmaceutical, Osaka, JP

9. The Shionogi BACE1 aspartyl protease inhibitor, atabecestat (JNJ-54861911) is an oral, brain-penetrant compound that was advanced into the EARLY Ph. IIb/III clinical trial for treatment of preclinical Alzheimer’s…

 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.